<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794958</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-68723</org_study_id>
    <secondary_id>CCT5068</secondary_id>
    <nct_id>NCT05794958</nct_id>
  </id_info>
  <brief_title>Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel</brief_title>
  <official_title>A Phase Ib, Open Label Study to Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kite Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell&#xD;
      Lymphoma (LBCL) who are at high risk of relapse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">April 1, 2038</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2038</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicities,dose limiting toxicity (DLT) of a second dose of AxiCel (Axi-Cel2) in adults with relapsed/refractory high-risk LBCL.</measure>
    <time_frame>28 days</time_frame>
    <description>Subjects will be assessment for dose limiting toxicity (DLT) for 28 days after the infusion of Axi-Cel-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Safety Run-in phase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First three patients (maximum of 6) will receive 0.5 x 106/kg CART cells (25% standard dose) as reinfusion product between days 7 through 14 if CRS/ICANS has resolved to a grade 1 or less.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 20 evaluable subjects will receive the target dose of AxiCel infusion to evaluate efficacy of Axi-Cel-2 in adults with high risk relapsed/refractory LBCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Safety Run-in phase</arm_group_label>
    <other_name>(Axi-cel-2)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis: Histologically confirmed aggressive B cell NHL including the following&#xD;
             types defined by WHO 2008:&#xD;
&#xD;
               -  Diffuse large B cell lymphoma (DLBCL); OR&#xD;
&#xD;
               -  primary mediastinal (thymic) large B cell lymphoma; OR&#xD;
&#xD;
               -  transformation of follicular lymphoma (TFL), marginal zone lymphoma to DLBCL; OR&#xD;
&#xD;
               -  high grade B-cell Lymphoma NOS will also be included&#xD;
&#xD;
          2. Patients must be considered high-risk lymphoma (defined as LDH greater than upper&#xD;
             limit of normal per institutional cut-off) at or within two weeks of leukapheresis.&#xD;
&#xD;
          3. Subjects must have received at least and a maximum one prior line of therapy for LBCL&#xD;
             indication (i.e subjects receiving second line standard of care Axi-Cel will be&#xD;
             enrolled in this study).&#xD;
&#xD;
          4. At least 1 measurable lesion on PET-CT or CT scan. If the only measurable disease is&#xD;
             lymph-node disease, at least 1 lymph node should be ≥ 1.5 cm.&#xD;
&#xD;
          5. Age 18 years or older&#xD;
&#xD;
          6. Eastern cooperative oncology group (ECOG) performance status of 0 or 1. ECOG 2&#xD;
             permitted if performance status is solely attributed to lymphoma.&#xD;
&#xD;
          7. Normal Organ and Marrow Function&#xD;
&#xD;
               -  ANC ≥ 1,000/uL&#xD;
&#xD;
               -  Platelet count ≥ 75,000/uL&#xD;
&#xD;
               -  Adequate renal, hepatic, pulmonary and cardiac function defined as:&#xD;
&#xD;
                    -  Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min&#xD;
&#xD;
                    -  Serum ALT or AST ≤ 2.5 x ULN (except in subjects with liver involvement by&#xD;
                       lymphoma)&#xD;
&#xD;
                    -  Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.&#xD;
&#xD;
                    -  Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as&#xD;
                       determined by an Echocardiogram.&#xD;
&#xD;
               -  No clinically significant pleural effusion or ascites&#xD;
&#xD;
               -  Baseline oxygen saturation &gt; 92% on room air&#xD;
&#xD;
          8. Ability to understand and the willingness to sign the written IRB-approved informed&#xD;
             consent document. Subjects unable to give informed consent will not be eligible for&#xD;
             this study.&#xD;
&#xD;
          9. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (females who have undergone surgical sterilization or who have been postmenopausal for&#xD;
             at least 2 years are not considered to be of childbearing potential)&#xD;
&#xD;
         10. Contraception: Subjects of child-bearing or child-fathering potential must be willing&#xD;
             to practice birth control from the time of enrollment on this study and for twelve&#xD;
             (12) months after receiving the preparative lymphodepletion regimen.&#xD;
&#xD;
         11. If prior CD19 directed therapy, demonstrates CD19 positivity by biopsy (Flow cytometry&#xD;
             or immunohistochemistry per the institutional criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with CAR-T or adoptive cell therapy.&#xD;
&#xD;
          2. Prior allogeneic transplant.&#xD;
&#xD;
          3. No bridging therapy permitted except for steroids or radiotherapy (bridging therapy&#xD;
             with steroids e.g. dexamethasone 40 mg for 5 days or radiotherapy is permitted).&#xD;
             Measurable non-irradiated lesion post-apheresis needed for enrollment.&#xD;
&#xD;
          4. Active central nervous system disease from lymphoma. MRI of the brain with no evidence&#xD;
             of CNS lymphoma if prior history of CNS involvement.&#xD;
&#xD;
          5. Prior history of allergic reactions or severe infusion reaction to Axi-Cel or any of&#xD;
             the reagents used in the Axi-Cel infusion.&#xD;
&#xD;
          6. History of Richter's transformation of chronic leukemic lymphoma, small lymphocytic&#xD;
             lymphoma, or lymphoplasmacytic lymphoma.&#xD;
&#xD;
          7. Any medical condition that in the judgement of the investigator is likely to interfere&#xD;
             with assessment of safety or efficacy of study treatment.&#xD;
&#xD;
          8. Women who are pregnant or breastfeeding&#xD;
&#xD;
          9. History of invasive malignancy unless the patient has been disease-free for five&#xD;
             years.&#xD;
&#xD;
               -  Exception: Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder,&#xD;
                  and breast) is eligible.&#xD;
&#xD;
               -  Hormonal therapy in subjects in remission &gt;1 year will be allowed.&#xD;
&#xD;
         10. History of stroke or transient ischemic attack within 12 months before enrollment, or&#xD;
             seizure disorders requiring active anticonvulsive medication.&#xD;
&#xD;
         11. In the investigator's judgment, the subject is unlikely to complete all study specific&#xD;
             visits or procedures, including follow-up visits, or comply with the study&#xD;
             requirements for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saurabh Dahiya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Chyan, MPH</last_name>
    <phone>(650) 725-8130</phone>
    <email>kchyan@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kelly Chyan, MPH</last_name>
      <phone>650-725-8130</phone>
      <email>kchyan@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sally Arai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Johnston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Lowsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Everett Meyer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Negrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Rezvani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Shizuru, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Kai Weng, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Praveen Shiraz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Frank, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Surbhi Sidana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori Muffly, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melody Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David B. Miklos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

